FDA Approves First Gene Therapy for Bladder Cancer

On December 16, 2022, the U.S. Food and Drug Administration (FDA) approved nadofaragene firadenovec-vncg for treating adult patients with high-risk Bacillus Calmette-Guérin unresponsive non-muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors. It is the first gene therapy approved for bladder cancer.

For more information, read the FDA announcement.

Posted 12/19/2022